Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report
Yan Zhang,1 Bixiu He,2 Dongbo Zhou,2 Min Li,1 Chengping Hu1 1Department of Respiratory Medicine, Xiangya Hospital (Key Cite of National Clinical Research Center for Respiratory Disease), Central South University, Changsha, Hunan, P.R. China; 2Department of Gerontology, Xiangya Hospital, Central Sou...
Main Authors: | Zhang Y, He B, Zhou D, Li M, Hu C |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-12-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/newly-emergent-acquired-egfr-exon-18-g724s-mutation-after-resistance-o-peer-reviewed-article-OTT |
Similar Items
-
Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
by: Wang Yuli, et al.
Published: (2016-01-01) -
A case report of toxic epidermal necrolysis associated with AZD-9291
by: Wang J, et al.
Published: (2018-07-01) -
Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
by: Saad N, et al.
Published: (2017-03-01) -
The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
by: Xuejiao Liu, et al.
Published: (2019-05-01) -
Calcium Regulates HCC Proliferation as well as EGFR Recycling/Degradation and Could Be a New Therapeutic Target in HCC
by: Teresa Maria Elisa Modica, et al.
Published: (2019-10-01)